Acquired resistance to tyrosine kinase inhibitors during cancer therapy

Current Opinion in Genetics and Development

Volumn 18, Issue 1, 2008, Pages 73-79

  Engelman, Jeffrey A ^a   Settleman, Jeffrey ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; BCR ABL PROTEIN; BIBW 2992; CL 387785; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; HEAT SHOCK PROTEIN 90; IMATINIB; MP 470; NILOTINIB; PELITINIB; PF 00299804; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; VALATINIB;

ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVATION; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 43749107912     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2008.01.004     Document Type: Review

References (59)

1. Giamas G., Stebbing J., Vorgias C.E., and Knippschild U. Protein kinases as targets for cancer treatment. Pharmacogenomics 8 (2007) 1005-1016
2. Lengyel E., Sawada K., and Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med 7 (2007) 77-84
3. Steeghs N., Nortier J.W., and Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 14 (2007) 942-953
4. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2005) 172-187
5. Shannon K.M. Resistance in the land of molecular cancer therapeutics. Cancer Cell 2 (2002) 99-102
6. Haber D.A., Bell D.W., Sordella R., Kwak E.L., Godin-Heymann N., Sharma S.V., Lynch T.J., and Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 70 (2005) 419-426
7. Sleijfer S., Wiemer E., Seynaeve C., and Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 12 (2007) 719-726
8. Burgess M.R., and Sawyers C.L. Treating imatinib-resistant leukemia: the next generation targeted therapies. Sci World J 6 (2006) 918-930
9. O'Hare T., Corbin A.S., and Druker B.J. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 16 (2006) 92-99
10. Gorre M.E., and Sawyers C.L. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 9 (2002) 303-307
11. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8 (2007) 1018-1029
12. Melo J.V., and Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 249 (2007) 121-132
13. Gambacorti-Passerini C., Barni R., le Coutre P., Zucchetti M., Cabrita G., Cleris L., Rossi F., Gianazza E., Brueggen J., Cozens R., et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92 (2000) 1641-1650
14. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880. This report demonstrated for the first time that acquired resistance to imatinib therapy in CML patients is frequently associated with mutations in the ABL kinase domain or with amplification of the BCR-ABL gene. These studies revealed the recurrent T315I substitution that is seen at high frequency in this treatment setting.
15. Hochhaus A., and La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18 (2004) 1321-1331
16. Jilani I., Kantarjian H., Gorre M., Cortes J., Ottmann O., Bhalla K., Giles F.J., and Albitar M. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res (2007)
17. Griswold I.J., MacPartlin M., Bumm T., Goss V.L., O'Hare T., Lee K.A., Corbin A.S., Stoffregen E.P., Smith C., Johnson K., et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 26 (2006) 6082-6093. This report demonstrated that some of the acquired resistance mutations of the ABL kinase domain seen in imatinib-treated CML patients give rise to a protein that has increased oncogenic activity in in vitro transformation assays. Such findings support a dual role for these mutations in drug resistance and tumorigenic potential.
18. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., and Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7 (2007) 345-356
19. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401. This report describes the first findings demonstrating that dasatinib can overcome the biochemical imatinib-resistance associated with many of the ABL kinase domain mutations seen in patient specimens from imatinib-treated CML cases. These studies paved the way for clinical studies of dasatinib that revealed its efficacy as a second-generation inhibitor.
20. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551. This report describes the first clinical studies of nilotinib, a second-generation ABL kinase inhibitor, demonstrating clinical activity in some imatinib-resistant CML patients.
21. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K.P., and Hughes T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99 (2002) 3472-3475
22. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., and Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109 (2007) 500-502
23. O'Hare T., Eide C.A., and Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110 (2007) 2242-2249
24. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., and Sawyers C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117 (2007) 2562-2569. This analysis of clinical specimens from CML patients sequentially treated with imatinib followed by dasatinib demonstrated that secondary drug resistance seen in these patients is associated with the acquisition of drug-resistant compound mutants of the ABL kinase domain, thereby highlighting the potential danger of such sequential treatment. The study also revealed the ability of the aurora kinase inhibitor, VX-680 to inhibit some of the documented imatinib-resistance mutants, suggesting a combination drug strategy that includes VX-680 and imatinib.
25. Rubin B.P., Heinrich M.C., and Corless C.L. Gastrointestinal stromal tumour. Lancet 369 (2007) 1731-1741
26. Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V., Booth B.P., Verbois S.L., Morse D.E., Liang C.Y., et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13 (2007) 1367-1373
27. Bauer S., Yu L.K., Demetri G.D., and Fletcher J.A. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66 (2006) 9153-9161
28. Peng C., Li D., and Li S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 6 (2007) 2227-2231
29. Peng C., Brain J., Hu Y., Goodrich A., Kong L., Grayzel D., Pak R., Read M., and Li S. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110 (2007) 678-685. This study made use of a mouse model of BCR-ABL-induced leukemia to demonstrate a potential role for HSP90 inhibitors in overcoming the recurrent imatinib-resistance mutation T315I.
30. Fletcher J.A., and Rubin B.P. KIT mutations in GIST. Curr Opin Genet Dev 17 (2007) 3-7
31. Mahadevan D., Cooke L., Riley C., Swart R., Simons B., Della Croce K., Wisner L., Iorio M., Shakalya K., Garewal H., et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26 (2007) 3909-3919
32. Sawabu T., Seno H., Kawashima T., Fukuda A., Uenoyama Y., Kawada M., Kanda N., Sekikawa A., Fukui H., Yanagita M., et al. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinogen 46 (2007) 155-164
33. Ito T., Tanaka H., and Kimura A. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol 78 (2007) 417-431
34. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004) 13306-13311. This report was among the first clinical studies to identify frequent EGFR kinase domain mutations in nonsmokers that exhibit clinical response to the EGFR inhibitors gefitinib and erlotinib.
35. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500. This report was among the first to identify activating EGFR kinase mutations in NSCLC and to correlate the presence of such mutations with clinical sensitivity to gefitinib treatment.
36. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139. This report was among the first to identify activating EGFR kinase mutations in NSCLC and to correlate the presence of such mutations with clinical sensitivity to gefitinib treatment.
37. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., Fong K.M., Lee H., Toyooka S., Shimizu N., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
38. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 (2005) 786-792. This report was among the first to demonstrate that the T790M mutation within the EGFR kinase domain can arise in the context of acquired resistance to EGFR-targeted therapy in NSCLC and that the mutation confers biochemical insensitivity to gefitinib.
39. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) 1-11. This report was among the first to demonstrate that the T790M mutation within the EGFR kinase domain arises at a significant frequency in the context of acquired resistance to EGFR-targeted therapy in NSCLC and that the mutation confers biochemical insensitivity to gefitinib and erlotinib.
40. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., Tada H., Kuwano H., and Mitsudomi T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12 (2006) 5764-5769
41. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., Chiang A., Yang G., Ouerfelli O., Kris M.G., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12 (2006) 6494-6501
42. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043. This report demonstrated the second documented mechanism of acquired resistance to EGFR kinase inhibitor therapy in NSCLC. The authors found that amplification of the MET gene is associated with acquired drug resistance in a subset of cases and that combined inhibition of MET and EGFR kinases may constitute a therapeutic strategy to overcome such resistance.
43. Antonescu C.R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., Leversha M.A., Jeffrey P.D., Desantis D., Singer S., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
44. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102 (2005) 7665-7670. This report demonstrated that irreversible EGFR kinase inhibitors can overcome the resistance to gefitinib and erlotinib associated with the acquisition of the T790M EGFR mutation seen in about half of the cases of acquired drug resistance in NSCLC. The findings supported a rationale for clinical testing of the irreversible class of EGFR inhibitors.
45. Kobayashi S., Ji H., Yuza Y., Meyerson M., Wong K.K., Tenen D.G., and Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65 (2005) 7096-7101. This report demonstrated that irreversible EGFR kinase inhibitors can overcome the resistance to gefitinib and erlotinib associated with the acquisition of the T790M EGFR mutation seen in about half of the cases of acquired drug resistance in NSCLC. The findings supported a rationale for clinical testing of the irreversible class of EGFR inhibitors.
46. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borras A.M., Gale C.M., Naumov G.N., Yeap B.Y., Jarrell E., Sun J., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116 (2006) 2695-2706. This report demonstrated that the recurrent T790M EGFR mutation associated with acquired resistance to EGFR kinase inhibitors in NSCLC may be under-represented in the genome of tumor cells because of amplification of non-T790M alleles, highlighting the potential importance of more sensitive allele-specific detection methods to detect this allele in clinical specimens.
47. Li D., Shimamura T., Ji H., Chen L., Haringsma H.J., McNamara K., Liang M.C., Perera S.A., Zaghlul S., Borgman C.L., et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12 (2007) 81-93
48. Regales L., Balak M.N., Gong Y., Politi K., Sawai A., Le C., Koutcher J.A., Solit D.B., Rosen N., Zakowski M.F., et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2 (2007) e810
49. Ogino A., Kitao H., Hirano S., Uchida A., Ishiai M., Kozuki T., Takigawa N., Takata M., Kiura K., and Tanimoto M. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 67 (2007) 7807-7814
50. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
51. Godin-Heymann N., Bryant I., Rivera M.N., Ulkus L., Bell D.W., Riese II D.J., Settleman J., and Haber D.A. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 67 (2007) 7319-7326
52. Greulich H., Chen T.H., Feng W., Janne P.A., Alvarez J.V., Zappaterra M., Bulmer S.E., Frank D.A., Hahn W.C., Sellers W.R., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2 (2005) e313
53. Bell D.W., Gore I., Okimoto R.A., Godin-Heymann N., Sordella R., Mulloy R., Sharma S.V., Brannigan B.W., Mohapatra G., Settleman J., et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37 (2005) 1315-1316. This report described a pedigree associated with evidence of inherited susceptibility to lung adenocarcinoma that was genetically linked to a germline EGFR kinase domain mutation T790M, the same mutant allele that was also found to be associated with acquired resistance to EGFR kinase inhibitors in NSCLC. This finding suggested a potential oncogenic role for this EGFR mutant, which was substantiated in subsequent studies.
54. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8923
55. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., Zhao F., Vincent P.W., Naumov G.N., Bradner J.E., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67 (2007) 11924-11932
56. Shimamura T., Lowell A.M., Engelman J.A., and Shapiro G.I. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65 (2005) 6401-6408
57. Yamasaki F., Johansen M.J., Zhang D., Krishnamurthy S., Felix E., Bartholomeusz C., Aguilar R.J., Kurisu K., Mills G.B., Hortobagyi G.N., et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 67 (2007) 5779-5788
58. Vogt P.K., Kang S., Elsliger M.A., and Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32 (2007) 342-349
59. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (2007) 395-402